Holen Sie sich die Stockscreener-App
45.99
3.65%
-1.74
Handel nachbörslich:
46.01
0.02
+0.04%
Schlusskurs vom Vortag:
$47.73
Offen:
$47.215
24-Stunden-Volumen:
4.20M
Relative Volume:
0.63
Marktkapitalisierung:
$18.25B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-5.6456
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
-6.26%
1M Leistung:
-15.38%
6M Leistung:
+58.42%
1J Leistung:
+66.15%
1-Tages-Spanne:
$45.67
$48.52
1-Wochen-Bereich:
$45.40
$51.90
52-Wochen-Spanne:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
45.99 | 18.94B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
435.71 | 113.14B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
601.65 | 64.60B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
862.18 | 54.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.22 | 39.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.19 | 31.79B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna, Inc. $MRNA Shares Sold by Letko Brosseau & Associates Inc. - MarketBeat
Moderna Inc stock (US60770K1079): Legal chief share sale and vaccine pipeline keep volatility high - AD HOC NEWS
Moderna Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Moderna’s mRNA-4194 cleared for clinic for Lynch syndrome - BioWorld News
Moderna Inc. stock (US60770K1034): Bank of America lifts price target after strong run - AD HOC NEWS
Does Moderna Need to Start Making Money? - The Globe and Mail
Does Moderna Need to Start Making Money? - The Motley Fool
Capital World Investors Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome - Investing News Network
AIPLA, NAM Rally Behind Moderna's Fight Over Vax Patents - Law360
Moderna’s Lynch syndrome cancer vaccine trial gets UK approval - Investing.com UK
Inherited cancer risk for 1 in 300: Moderna mRNA trial targets Lynch syndrome - Stock Titan
Moderna CLO Klinger sells $173,550 in shares By Investing.com - Investing.com India
Moderna CLO Klinger sells $173,550 in shares - Investing.com
Moderna (MRNA) legal chief sells 3,471 shares, exercises options and RSUs - Stock Titan
Moderna (MRNA) CFO details RSU vesting and tax share withholding in Form 4 - Stock Titan
MRNA Maintained by B of A Securities -- Price Target Raised to $34 - GuruFocus
Moderna (NASDAQ:MRNA) Price Target Raised to $34.00 - MarketBeat
Moderna, Inc. (MRNA) Stock Analysis: Evaluating The Potential Amidst Volatility - DirectorsTalk Interviews
Havemeyer Place LP Takes Position in Moderna, Inc. $MRNA - MarketBeat
CIBC Asset Management Inc Increases Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Aufman Associates Inc Has $1.27 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
How Investors May Respond To Moderna (MRNA) mRNA Advances in Personalized Cancer and Emerging Infectious Diseases - Yahoo Finance
Norges Bank Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
MRNA Stock Quote Price and Forecast - CNN
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Yahoo Finance
Moderna gets good news as it searches for life after Covid - Yahoo Finance Singapore
[144] Moderna, Inc. SEC Filing - Stock Titan
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna Stock: Is MRNA Outperforming the Health Care Sector? - Yahoo Finance
Moderna Inc. stock (US60770K1034): EMA committee backs new RSV vaccine as shares bounce on Nasdaq - AD HOC NEWS
Moderna (MRNA) Climbs 7.5% Ahead of Next Week’s Key Updates - Insider Monkey
Moderna rallies on renewed optimism around its Merck-partnered melanoma vaccine program - Quiver Quantitative
Moderna (MRNA) CFO exercises 2,475 RSUs, 1,197 shares withheld for taxes - Stock Titan
Moderna (MRNA) CLO converts RSUs into stock while 1,047 shares withheld for taxes - Stock Titan
Moderna (MRNA) president exercises RSUs, reports tax share withholding - Stock Titan
Moderna (NASDAQ:MRNA) Trading 8.1% HigherShould You Buy? - MarketBeat
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion - Investing News Network
HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery - marketscreener.com
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 - Yahoo Finance
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™” - Yahoo Finance
Moderna CEPI Ebola Vaccine Work Highlights Broader Infectious Disease Ambitions - Yahoo Finance
Moderna to Present at Upcoming Conference in June 2026 - Investing News Network
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - Zacks Investment Research
UBS Lifts Valuation On Moderna, Inc. (MRNA) Ahead of Key Pipeline Catalysts - Insider Monkey
Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus - Gotrade
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival - BioSpace
Moderna, Inc. $MRNA Shares Acquired by Lingotto Investment Management LLP - MarketBeat
Moderna and other groups get $60mln to develop Ebola vaccine - ZAWYA
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus - Black Hills Pioneer
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Jun 04 '26 |
Sale |
50.00 |
3,471 |
173,550 |
67,468 |
2.20%
2.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):